Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-term Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Nivolumab Plus Chemotherapy as Neoadjuvant Therapy in France

NCT06735781 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT06735781
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06735781 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-term Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Nivolumab Plus Chemotherapy as Neoadjuvant Therapy in France
Lead sponsor
Bristol-Myers Squibb
Phase
Observational
Overall status
Completed
Start date
September 5, 2024
Completion date
October 1, 2024
Enrollment
101 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer (nsclc)